TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

• Change in QT/QTc interval for TMC435 therapeutic dose versus placebo [ Time Frame: 24-hour measurement on Day 7 of Treatment Session A and D ] [ Designated as safety issue: No ]
  
• Change in QT/QTc interval for TMC435 supratherapeutic dose versus placebo [ Time Frame: 24-hour measurement on Day 7 of Treatment Session B and D ] [ Designated as safety issue: No ]
  

• RR interval, HR, PR interval, QRS interval and ECG morphology [ Time Frame: 1-hour predose measurement on Day 1 of every treatment session ] [ Designated as safety issue: No ]
  
• RR interval, HR, PR interval, QRS interval and ECG morphology [ Time Frame: 24-hour measurement on Day 7 of every treatment session ] [ Designated as safety issue: No ]
  
• Pharmacokinetics of 150 mg TMC435 once daily for 7 days [ Time Frame: Predose on Day 1 of every treatment and on Days 5 and 6 of Treatments A and B. 24 hour profile on Day 7 of Treatment A and B ] [ Designated as safety issue: No ]
  
• Pharmacokinetics of 350 mg TMC435 once daily for 7 days [ Time Frame: Predose on Day 1 of every treatment and on Days 5 and 6 of Treatments A and B. 24 hour profile on Day 7 of Treatment A and B ] [ Designated as safety issue: No ]
  
• Changes from baseline for electrocardiogram (ECG) and physical examination [ Time Frame: During all treatment sessions: Daily safety ECG from Day -1 to Day 9 with on Day 1 and 7 an additional safety ECG at 5h timepoint plus at screening and follow-up visits. Physical examination at screening, on Day 8 and at the follow-up visits ] [ Designated as safety issue: No ]
  
• Number of participants with adverse events and severity of adverse events [ Time Frame: From signing of informed consent onwards until last trial-related visit ] [ Designated as safety issue: No ]
  
• Changes from baseline and percentage of subjects with abnormal values for laboratory parameters [ Time Frame: At screening, on Days -1, 1, 5, 8 of all treatment sessions and at the follow-up visits ] [ Designated as safety issue: No ]
  
• Changes from baseline and percentage of subjects with abnormal values for pulse and blood pressure [ Time Frame: At screening, daily from Day -1 to Day 9 with a second measurement on Day 7 of all treatment sessions and at the follow-up visits ] [ Designated as safety issue: No ]
  
• Difference of QTc between moxifloxacin treatment and placebo treatment as a measure for trial sensitivity [ Time Frame: On Day 7 of Treatment C and D, at the 2, 3, 4 and 5 hour timepoints ] [ Designated as safety issue: No ]
  

This is a double-blind, double-dummy, randomized, 4-period cross-over, placebo- and positive-controlled, Phase I study. This means neither the study doctor nor the participants know in which treatment session you will receive which active medication or matching placebo. Every participant will receive 4 treatment sessions (Treatments A, B, C and D) in a different order. The order in which you receive the treatment sessions is determined by chance, like tossing a coin. The purpose of the study is to evaluate the effect of TMC435 on the results of electrocardiograms (electric recording of the heart). Two dose regimens of TMC435 will be tested, ie, 150 mg once daily (the dose that will be given to patients) and 350 mg once daily (a dose higher than the one that will be given to patients), administered for 7 days. A single dose of 400 mg moxifloxacin will be used as a positive control to assess trial sensitivity. The trial population will consist of 60 healthy volunteers of which approximately 18 will be females. In each treatment, dummy capsules will be added in order to have the same number of capsules in each treatment. Treatment A will consist of 150 mg TMC435 once daily for 7 days (2 capsules of TMC435 and 2 capsules placebo on days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment B will consist of 350 mg TMC435 once daily for 7 days (4 capsules of TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment C will consist of 400 mg moxifloxacin on Day 7 (4 capsules of placebo for TMC435 on Days 1-7, 1 moxifloxacin tablet on Day 7). In Treatment D only placebo will be given (4 capsules of placebo for TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). There will be a washout period of at least 10 days between subsequent treatments. A pharmacogenomic blood sample (DNA sample, blood sample from which your genetic information can be analyzed) will be collected from all volunteers and will be analyzed upon observation of irregular electrocardiogram during the study. The purpose is to see if irregularities in the electrocardiogram can be linked to genetic variants. DNA samples may also be analyzed for additional genes related to pharmacokinetics (what the body does with the drug), pharmacodynamics (what the drug does to your body) or safety and tolerability of TMC435 during the study, as necessary. Two oral doses of TMC435 (150 or 350 mg) or placebo will be given once daily for 7 consecutive days. A single dose of moxifloxacin 400 mg will be administered orally on Day 7 in one of the treatment sessions only.